Patients with chronic liver disease & intractable pruritus

Nalfurafine capsules 2.5 μg, oral dispersing tablets 2.5 μg) in 1,186 patients with chronic liver disease and intractable pruritus.

Related Keywords

Japan ,Japanese ,Nalfurafine Remitch ,Toray Industries Inc ,Japanese Ministry Of Health ,Administration Child ,Japanese Pharmaceutical Affairs Law ,Research Laboratories Of Toray Industries Inc ,Drug Use ,Pharmaceutical Research Laboratories ,Toray Industries ,Visual Analog Scale ,Specific Drug Use Survey ,Japanese Ministry ,Good Post Marketing Study Practice ,Conducting Post Marketing Surveillance ,Japanese Pharmaceutical Affairs ,Drug Dependence ,Adverse Drug Reactions ,Japanese Law ,Medical Devices Law ,Adverse Drug ,Patient Characteristics ,General Assessment ,Ditch Improvement ,Baseline Patient ,Hepatic Cancer ,Daily Dose ,Patients Treated ,Dose Elevation ,Treatment Duration ,Days Nalfurafine Was Given ,After First Dose ,Severity Score Results ,